Insulin glargine biosimilar - Boehringer Ingelheim/Eli Lilly

Drug Profile

Insulin glargine biosimilar - Boehringer Ingelheim/Eli Lilly

Alternative Names: Abasaglar; Abasria; Basalgar; LY-2963016; LY2963016 U-100; LY2963016 U-200

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Boehringer Ingelheim; Eli Lilly
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 15 Nov 2016 Eli Lilly plans a phase I trial in Healthy volunteers in Singapore (NCT02955953)
  • 01 Nov 2016 Eli Lilly initiates a phase I trial in Healthy volunteers in Singapore (NCT02955953)
  • 01 Jul 2016 Eli Lilly and Boehringer Ingelheim complete the phase III ELEMENT 5 trial for Type-2 diabetes mellitus in USA, India, Puerto Rico, Russia, South Korea, Taiwan and Turkey (NCT02302716)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top